Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

doi:10.3748/wjg.15.2290

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2466)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

315

HTML

1948

Figures (1-2)

203

Sum=2466

May 14, 2009 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. May 14, 2009; 15(18): 2290-2292
Published online May 14, 2009. doi: 10.3748/wjg.15.2290

Full Size Figure Download Figure

Figure 1 Liver necropsy stained with antibody against hepatitis B core antigen. FCH is also characterized by massive expression of hepatitis B core antigen (nuclear and cytoplasmic).

Citation: Ceballos-Viro J, López-Picazo JM, Pérez-Gracia JL, Sola JJ, Aisa G, Gil-Bazo I. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J Gastroenterol 2009; 15(18): 2290-2292
URL: https://www.wjgnet.com/1007-9327/full/v15/i18/2290.htm
DOI: https://dx.doi.org/10.3748/wjg.15.2290